(Q43596024)

25 November 2017

Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity (English)

1 reference

25 November 2017

1 reference

5

Schally AV

1 reference

25 November 2017

Yakar S

1

1 reference

25 November 2017

Liu JL

2

1 reference

25 November 2017

Fernandez AM

3

1 reference

25 November 2017

Wu Y

4

1 reference

25 November 2017

Frystyk J

6

1 reference

25 November 2017

Chernausek SD

7

1 reference

25 November 2017

Mejia W

8

1 reference

25 November 2017

Le Roith D

9

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

25 November 2017

1 reference

25 November 2017

50

1 reference

25 November 2017

5

1 reference

25 November 2017

1110-1118

1 reference

Identification of enhanced serine kinase activity in insulin resistance

25 November 2017

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

The crucial role of a phosphatase in insulin resistance and obesity.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Growth hormone insulin-like growth factor I axis in insulin-dependent diabetes mellitus

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Inhibition of GH release of rats by new potent antagonists of growth hormone-releasing hormone (GH-RH).

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signaling

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin resistance--mechanisms, syndromes, and implications

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin-like growth factor I inhibits glucose-stimulated insulin secretion but does not impair glucose metabolism in normal humans

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin-like growth factor I: physiology, metabolic effects and clinical uses

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

IGF-I is required for normal embryonic growth in mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Normal growth and development in the absence of hepatic insulin-like growth factor I

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

JAK1-dependent phosphorylation of insulin receptor substrate-1 (IRS-1) is inhibited by IRS-1 serine phosphorylation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Expression of cobalamin transport proteins and cobalamin transcytosis by colon adenocarcinoma cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: effects of starvation, refeeding, and dieting

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Changes in the circulating IGF system during short-term fasting and refeeding in rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Genetic engineering in mice: impact on insulin signalling and action.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Suppression of insulin-like growth factor I during epidermal growth factor-induced growth retardation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Early neonatal death in mice homozygous for a null allele of the insulin receptor gene

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Role of insulin-like growth factors in embryonic and postnatal growth

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Transgenic models of growth hormone action

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Metabolic effects of hypopituitarism and acromegaly

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Different Effects of the GABAergic Agent Sodium Valproate on the Oxytocin Responses to Angiotensin II and Insulin-Induced Hypoglycemia in Normal Men

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.2337/DIABETES.50.5.1110

Identifiers

DOI

10.2337/DIABETES.50.5.1110

1 reference

25 November 2017

1 reference